Statement of Changes in Beneficial Ownership (4)
2020年6月27日 - 6:06AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person
*
Fecho Jeff |
2. Issuer Name and Ticker or Trading Symbol
ENDOLOGIX INC /DE/
[
ELGX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Quality Officer |
(Last)
(First)
(Middle)
2 MUSICK |
3. Date of Earliest Transaction
(MM/DD/YYYY)
6/25/2020 |
(Street)
IRVINE, CA 92618
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 6/25/2020 | | A | | 6172 (1) | A | $0 | 26371 | D | |
Common Stock | 6/25/2020 | | F | | 693 (2) | D | $0.8484 | 25678 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | This award was originally reported on a Form 3 filed with the Securities and Exchange Commission on June 17, 2019. 33% of the shares subject to this restricted stock unit award vested pursuant to the terms of this award. |
(2) | Shares withheld on June 25, 2020 to satisfy statutory minimum tax withholding obligations related to shares vested on June 25, 2020. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Fecho Jeff 2 MUSICK IRVINE, CA 92618 |
|
| Chief Quality Officer |
|
Signatures
|
Jeff Fecho by Timothy N. Brady Attorney-in-Fact for Reporting Person | | 6/26/2020 |
**Signature of Reporting Person | Date |
Endologix (NASDAQ:ELGX)
過去 株価チャート
から 2 2025 まで 3 2025
Endologix (NASDAQ:ELGX)
過去 株価チャート
から 3 2024 まで 3 2025
Real-Time news about Endologix Inc (ナスダック市場): 0 recent articles
その他のEndologix Inc /de/ニュース記事